Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH3G10 in STEMI
NCT03991143Phase 2Completed
- Sponsor
- Athera Biotechnologies AB
- Start
- Mar 2019
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing ATH3G10 with Placebo (2 arms). Primary endpoint: Left ventricular remodelling at 90 days. Started Mar 2019; status: completed.
02
Drugs
ABR-001
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03991143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991143.